TW201319080A - α－葡糖基橘皮苷之結晶與其用途 - Google Patents

α－葡糖基橘皮苷之結晶與其用途 Download PDF

Info

Publication number: TW201319080A
Authority: TW; Taiwan
Prior art keywords: crystal; glucosyl hesperidin; hesperidin; glucosyl; powder
Prior art date: 2011-08-01

Application number

TW101127785A

Other languages

English (en)

Chinese (zh)

Inventor

Takashi Shibuya

Seisuke Izawa

Original Assignee

Hayashibara Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-08-01

Filing date

2012-08-01

Publication date

2013-05-16

2012-08-01 Application filed by Hayashibara Co filed Critical Hayashibara Co

2013-05-16 Publication of TW201319080A publication Critical patent/TW201319080A/zh

Links

IMMBLRJLSYJQIZ-UNQGIHKMSA-N (2S)-7-[3,4-dihydroxy-5-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxymethyl]oxan-2-yl]oxy-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-2,3-dihydrochromen-4-one Chemical compound COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(OC3OC(COC4OC(C)C(O)C(O)C4O)C(OC4OC(CO)C(O)C(O)C4O)C(O)C3O)cc2O1 IMMBLRJLSYJQIZ-UNQGIHKMSA-N 0.000 title claims description 173
239000013078 crystal Substances 0.000 claims abstract description 231
239000000843 powder Substances 0.000 claims abstract description 58
239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 claims description 31
229940025878 hesperidin Drugs 0.000 claims description 31
239000003814 drug Substances 0.000 claims description 28
238000004458 analytical method Methods 0.000 claims description 24
239000002994 raw material Substances 0.000 claims description 22
230000003287 optical effect Effects 0.000 claims description 20
238000002425 crystallisation Methods 0.000 claims description 18
230000008025 crystallization Effects 0.000 claims description 16
229910052799 carbon Inorganic materials 0.000 claims description 12
125000004430 oxygen atom Chemical group O* 0.000 claims description 10
125000004432 carbon atom Chemical group C* 0.000 claims description 3
238000004811 liquid chromatography Methods 0.000 claims description 2
239000003795 chemical substances by application Substances 0.000 abstract description 7
229940108690 glucosyl hesperidin Drugs 0.000 abstract description 4
239000000463 material Substances 0.000 abstract description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 45
QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 27
QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 27
APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 27
VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 27
QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical group C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 27
ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 27
239000000243 solution Substances 0.000 description 25
239000000126 substance Substances 0.000 description 20
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
238000002441 X-ray diffraction Methods 0.000 description 17
238000000034 method Methods 0.000 description 16
239000000047 product Substances 0.000 description 15
238000004128 high performance liquid chromatography Methods 0.000 description 14
210000004027 cell Anatomy 0.000 description 12
229930182470 glycoside Natural products 0.000 description 10
150000002338 glycosides Chemical class 0.000 description 10
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
238000010586 diagram Methods 0.000 description 8
125000004435 hydrogen atom Chemical group [H]* 0.000 description 8
239000000203 mixture Substances 0.000 description 8
229940124597 therapeutic agent Drugs 0.000 description 8
150000001721 carbon Chemical group 0.000 description 7
239000007787 solid Substances 0.000 description 7
239000007864 aqueous solution Substances 0.000 description 6
230000004900 autophagic degradation Effects 0.000 description 6
201000010099 disease Diseases 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
229940079593 drug Drugs 0.000 description 6
230000000694 effects Effects 0.000 description 6
238000004519 manufacturing process Methods 0.000 description 6
238000012360 testing method Methods 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
-1 Alpha-glucosyl Chemical class 0.000 description 5
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
239000002537 cosmetic Substances 0.000 description 5
238000001914 filtration Methods 0.000 description 5
239000008103 glucose Substances 0.000 description 5
238000002347 injection Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
150000002894 organic compounds Chemical class 0.000 description 5
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
239000003480 eluent Substances 0.000 description 4
238000001000 micrograph Methods 0.000 description 4
239000002244 precipitate Substances 0.000 description 4
238000001556 precipitation Methods 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 4
239000002904 solvent Substances 0.000 description 4
239000000725 suspension Substances 0.000 description 4
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
208000012659 Joint disease Diseases 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
238000004440 column chromatography Methods 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
239000008187 granular material Substances 0.000 description 3
238000010438 heat treatment Methods 0.000 description 3
239000012535 impurity Substances 0.000 description 3
238000005259 measurement Methods 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
238000012545 processing Methods 0.000 description 3
238000003756 stirring Methods 0.000 description 3
208000019553 vascular disease Diseases 0.000 description 3
ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 2
208000006770 Ascorbic Acid Deficiency Diseases 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
208000035143 Bacterial infection Diseases 0.000 description 2
208000024172 Cardiovascular disease Diseases 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
229940123464 Thiazolidinedione Drugs 0.000 description 2
206010047623 Vitamin C deficiency Diseases 0.000 description 2
150000008065 acid anhydrides Chemical class 0.000 description 2
WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 description 2
108010044879 alpha-L-rhamnosidase Proteins 0.000 description 2
125000004429 atom Chemical group 0.000 description 2
238000000354 decomposition reaction Methods 0.000 description 2
238000001514 detection method Methods 0.000 description 2
235000013305 food Nutrition 0.000 description 2
125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
239000007937 lozenge Substances 0.000 description 2
239000012528 membrane Substances 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
230000000704 physical effect Effects 0.000 description 2
229910000160 potassium phosphate Inorganic materials 0.000 description 2
235000011009 potassium phosphates Nutrition 0.000 description 2
230000002265 prevention Effects 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
239000008213 purified water Substances 0.000 description 2
238000004445 quantitative analysis Methods 0.000 description 2
238000011160 research Methods 0.000 description 2
125000000953 rutinose group Chemical group 0.000 description 2
208000010233 scurvy Diseases 0.000 description 2
238000005728 strengthening Methods 0.000 description 2
239000013589 supplement Substances 0.000 description 2
238000001308 synthesis method Methods 0.000 description 2
239000003826 tablet Substances 0.000 description 2
238000012546 transfer Methods 0.000 description 2
238000006276 transfer reaction Methods 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
229940088594 vitamin Drugs 0.000 description 2
239000011782 vitamin Substances 0.000 description 2
229930003231 vitamin Natural products 0.000 description 2
235000013343 vitamin Nutrition 0.000 description 2
150000008494 α-glucosides Chemical class 0.000 description 2
OEANUJAFZLQYOD-CXAZCLJRSA-N (2r,3s,4r,5r,6r)-6-[(2r,3r,4r,5r,6r)-5-acetamido-3-hydroxy-2-(hydroxymethyl)-6-methoxyoxan-4-yl]oxy-4,5-dihydroxy-3-methoxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](OC)O[C@H](CO)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](OC)[C@H](C(O)=O)O1 OEANUJAFZLQYOD-CXAZCLJRSA-N 0.000 description 1
UFSKIYBOKFBSOA-MLYSRARTSA-N (2r,3s,4s,5r)-2-(hydroxymethyl)-6-octadecoxyoxane-3,4,5-triol Chemical compound CCCCCCCCCCCCCCCCCCOC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UFSKIYBOKFBSOA-MLYSRARTSA-N 0.000 description 1
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
235000007575 Calluna vulgaris Nutrition 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
108010025880 Cyclomaltodextrin glucanotransferase Proteins 0.000 description 1
229920000045 Dermatan sulfate Polymers 0.000 description 1
208000018522 Gastrointestinal disease Diseases 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
239000002211 L-ascorbic acid Substances 0.000 description 1
235000000069 L-ascorbic acid Nutrition 0.000 description 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
206010057249 Phagocytosis Diseases 0.000 description 1
ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
OVVGHDNPYGTYIT-VHBGUFLRSA-N Robinobiose Natural products O(C[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](C)O1 OVVGHDNPYGTYIT-VHBGUFLRSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
125000004018 acid anhydride group Chemical group 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000003708 ampul Substances 0.000 description 1
230000003064 anti-oxidating effect Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
230000003796 beauty Effects 0.000 description 1
244000309464 bull Species 0.000 description 1
210000000692 cap cell Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000003086 colorant Substances 0.000 description 1
229940116283 combination glucose Drugs 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
238000002447 crystallographic data Methods 0.000 description 1
230000007123 defense Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000002050 diffraction method Methods 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
108010030923 hesperidinase Proteins 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
230000001678 irradiating effect Effects 0.000 description 1
MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
230000037356 lipid metabolism Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000003550 marker Substances 0.000 description 1
239000013081 microcrystal Substances 0.000 description 1
210000004088 microvessel Anatomy 0.000 description 1
239000011707 mineral Substances 0.000 description 1
210000003470 mitochondria Anatomy 0.000 description 1
238000000302 molecular modelling Methods 0.000 description 1
239000000178 monomer Substances 0.000 description 1
239000005445 natural material Substances 0.000 description 1
210000003061 neural cell Anatomy 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000008782 phagocytosis Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000001698 pyrogenic effect Effects 0.000 description 1
229960001285 quercetin Drugs 0.000 description 1
235000005875 quercetin Nutrition 0.000 description 1
239000001397 quillaja saponaria molina bark Substances 0.000 description 1
OVVGHDNPYGTYIT-BNXXONSGSA-N rutinose Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1 OVVGHDNPYGTYIT-BNXXONSGSA-N 0.000 description 1
229930182490 saponin Natural products 0.000 description 1
150000007949 saponins Chemical class 0.000 description 1
238000004467 single crystal X-ray diffraction Methods 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
235000019187 sodium-L-ascorbate Nutrition 0.000 description 1
239000011755 sodium-L-ascorbate Substances 0.000 description 1
238000001694 spray drying Methods 0.000 description 1
238000005507 spraying Methods 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
230000000707 stereoselective effect Effects 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000012916 structural analysis Methods 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
230000002792 vascular Effects 0.000 description 1
238000001262 western blot Methods 0.000 description 1
230000002087 whitening effect Effects 0.000 description 1
230000029663 wound healing Effects 0.000 description 1
238000012982 x-ray structure analysis Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/06—Benzopyran radicals
- C07H17/065—Benzo[b]pyrans
- C07H17/07—Benzo[b]pyran-4-ones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Nutrition Science (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Psychiatry (AREA)
Heart & Thoracic Surgery (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Cardiology (AREA)
Physical Education & Sports Medicine (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Cosmetics (AREA)

TW101127785A 2011-08-01 2012-08-01 α－葡糖基橘皮苷之結晶與其用途 TW201319080A (zh)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP2011168720		2011-08-01

Publications (1)

Publication Number	Publication Date
TW201319080A true TW201319080A (zh)	2013-05-16

Family

ID=47629978

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW101127785A TW201319080A (zh)	2011-08-01	2012-08-01	α－葡糖基橘皮苷之結晶與其用途

Country Status (3)

Country	Link
JP (3)	JPWO2013018779A1 (fr)
TW (1)	TW201319080A (fr)
WO (1)	WO2013018779A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN106661073A (zh) *	2014-03-03	2017-05-10	株式会社林原	糖基橙皮素和其制造方法以及用途
CN107920981A (zh) *	2015-09-02	2018-04-17	株式会社林原	暗黄降低用皮肤外用剂

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP6678928B2 (ja) *	2014-08-20	2020-04-15	株式会社林原	経口美容剤
WO2022059775A1 (fr)	2020-09-17	2022-03-24	昭和電工株式会社	Activateur d'autophagie
JPWO2022059763A1 (fr) *	2020-09-17	2022-03-24
CN116507314A (zh)	2020-09-17	2023-07-28	株式会社力森诺科	自噬激活剂
JPWO2022059776A1 (fr) *	2020-09-17	2022-03-24

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP3060227B2 (ja) *	1989-06-03	2000-07-10	株式会社林原生物化学研究所	α―グリコシルヘスペリジンとその製造方法並びに用途
JP3833775B2 (ja) *	1996-06-26	2006-10-18	株式会社林原生物化学研究所	酵素処理ヘスペリジンおよびその製造方法ならびに酵素処理ヘスペリジンの使用方法
DE69821428T2 (de) *	1997-03-24	2004-12-16	Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo	Verfahren zur herstellung einer alpha-monoglucosylhesperidin-reichen substanz
JP2004323469A (ja) *	2003-04-28	2004-11-18	Ezaki Glico Co Ltd	Ｉｉ型糖尿病の予防、治療用の医薬組成物および食品
JP5132889B2 (ja) *	2006-02-27	2013-01-30	株式会社ポッカコーポレーション	神経成長因子増強剤

2012
- 2012-07-30 WO PCT/JP2012/069378 patent/WO2013018779A1/fr not_active Ceased
- 2012-07-30 JP JP2013526923A patent/JPWO2013018779A1/ja not_active Withdrawn
- 2012-08-01 TW TW101127785A patent/TW201319080A/zh unknown
2017
- 2017-01-31 JP JP2017015237A patent/JP6283429B2/ja active Active
2018
- 2018-01-26 JP JP2018012023A patent/JP2018080204A/ja not_active Withdrawn

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN106661073A (zh) *	2014-03-03	2017-05-10	株式会社林原	糖基橙皮素和其制造方法以及用途
EP3135682B1 (fr) *	2014-03-03	2021-08-25	Hayashibara Co., Ltd.	Composition de hespéridine glucosyle et son procédé de fabrication
CN107920981A (zh) *	2015-09-02	2018-04-17	株式会社林原	暗黄降低用皮肤外用剂

Also Published As

Publication number	Publication date
JP2018080204A (ja)	2018-05-24
JP6283429B2 (ja)	2018-02-21
JPWO2013018779A1 (ja)	2015-03-05
WO2013018779A1 (fr)	2013-02-07
JP2017071655A (ja)	2017-04-13

Publication	Publication Date	Title
JP6283429B2 (ja)	2018-02-21	α−グルコシルヘスペリジンの結晶とその用途
US9206215B2 (en)	2015-12-08	Hydrous crystalline 2-O-α-D-glucosyl-L-ascorbic acid, particulate composition comprising the same, their preparation and uses
JP3194145B2 (ja)	2001-07-30	４Ｇ―α―Ｄ―グルコピラノシルルチンとその製造方法並びに用途
JP5979376B2 (ja)	2016-08-24	溶解性の高いピロロキノリンキノン塩及びその製造方法
CN109134459B (zh)	2020-02-14	吡咯喹啉醌二钠盐晶体及其制备方法
CN102101836A (zh)	2011-06-22	S-奥拉西坦新晶型及其制备方法
CA2915222A1 (fr)	2011-12-01	Levoisovalerylspiramycine i, ii ou iii, preparations, procedes de preparation et utilisations associes
CN111423438B (zh)	2023-04-07	具有抗肿瘤活性的Eudistomins Y类衍生物及其制备方法和应用
KR101694710B1 (ko)	2017-01-10	(6s)-5-메틸 테트라히드로 엽산염 결정형 및 그 제조방법
RU2485121C1 (ru)	2013-06-20	Новые кристаллические формы адефовира дипивоксила и способы его получения
CN104650034A (zh)	2015-05-27	一种稳定的阿西替尼化合物
CN106518962A (zh)	2017-03-22	一种从酵母细胞中制备还原型谷胱甘肽的方法
Li et al.	2016	Physicochemical characterization of inclusion complex of catechin and glucosyl-β-cyclodextrin
CN102260291B (zh)	2012-08-29	一种核黄素磷酸钠化合物及其制备
JP5439671B2 (ja)	2014-03-12	抗がん剤
JP6141266B2 (ja)	2017-06-07	５´−Ｏ−α−Ｄ−グルコピラノシルアデノシン塩酸塩の結晶とその用途
CN104447542A (zh)	2015-03-25	博舒替尼一水合物及其制备方法
JP2877366B2 (ja)	1999-03-31	結晶状ｌ−アスコルビン酸−２−リン酸ナトリウム塩の製造法
Zalte et al.	2018	Preparation and characterization of etodolac co-crystals using 32 full factorial design
CN113677211A (zh)	2021-11-19	2-O-α-D-葡糖基-L-抗坏血酸的钾盐晶体及其制备方法
JP2021011455A (ja)	2021-02-04	フロレチン−４−α−グルコシドの結晶
JPS63104927A (ja)	1988-05-10	アルド−スリダクタ−ゼ阻害剤
US11008355B2 (en)	2021-05-18	Crystal of 3'-sialyllactose sodium salt n-hydrate, and process for producing same
JPS63165323A (ja)	1988-07-08	抗腫瘍剤
JP2019178073A (ja)	2019-10-17	含硫アミノ酸の塩を含む固形組成物、その製造方法及びその用途